

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

Flt3 ligand antibody [EP1140Y]

RRID:AB_2104974

Type: Antibody

Proper Citation

Abcam Cat# ab52648, RRID:AB_2104974

Antibody Information

URL: http://antibodyregistry.org/AB_2104974

Proper Citation: Abcam Cat# ab52648, RRID:AB_2104974

Target Antigen: Flt3 ligand antibody [EP1140Y]

Host Organism: rabbit

Clonality: monoclonal

Comments: validation status unknown, seller recommendations provided in 2012: Flow Cyt, ICC/IF, IHC-P, WB; Immunofluorescence; Immunocytochemistry; Immunohistochemistry - fixed; Western Blot; Immunohistochemistry; Flow Cytometry

Antibody Name: Flt3 ligand antibody [EP1140Y]

Description: This monoclonal targets Flt3 ligand antibody [EP1140Y]

Target Organism: human

Antibody ID: AB_2104974

Vendor: Abcam

Catalog Number: ab52648

Record Creation Time: 20250820T035033+0000

Record Last Update: 20250820T172006+0000

Ratings and Alerts

No rating or validation information has been found for Flt3 ligand antibody [EP1140Y].

No alerts have been found for Flt3 ligand antibody [EP1140Y].

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Momenilandi M, et al. (2024) FLT3L governs the development of partially overlapping hematopoietic lineages in humans and mice. *Cell*, 187(11), 2817.

Zhang Z, et al. (2022) Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo. *Frontiers in oncology*, 12, 974573.

Joshi SK, et al. (2021) The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance. *Cancer cell*, 39(7), 999.